admin – Page 6140 – Get News Story

Hernia Repair Market worth $5.1 billion by 2029 | MarketsandMarkets™

“prominent players in hernia repair are Ethicon Inc. (US), AbbVie Inc. (US), Medtronic plc (Ireland), Becton Dickinson and Company (US), Baxter International Inc. (US), B. Braun SE (Germany), W. L. Gore & Associates (US), Cook Group Inc (US), Integra Lifesciences Holdings Corporation (US)”

Browse 204 market data Tables and 41 Figures spread through 230 Pages and in-depth TOC on “Hernia Repair Market by Product (Mesh (Synthetic, Biologic), Suture (Absorbable, Non-Absorbable), Tack, Glue Applicator), Indication (Inguinal, Incisional, Umbilical, Epigastric, Femoral, Hiatal), Surgery, End-user – Global Forecast to 2029

Hernia Repair Market in terms of revenue was estimated to be worth $4.1 billion in 2024 and is poised to reach $5.1 billion by 2029, growing at a CAGR of 4.2% from 2024 to 2029 according to a new report by MarketsandMarkets™. Factors such as increasing hernia prevalence, rising geriatric population, technological advancement, increasing adoption of mesh in hernia repair surgeries, new product development, effectiveness of mesh repair and efficient reimbursement system are high growth prospects for the hernia repair market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203245450

The mesh segment is to register a significant growth rate over the forecast period of 2024-2029.

Based on the product, over the forecast period of 2024-2029, the mesh segment is to register a significant growth rate. The hernia repair product market is segmented into mesh, sutures and mesh fixators. The hernia mesh segment comprises synthetic and biologic mesh. Sutures are sub-segmented into absorbable and non- absorbable sutures. The hernia mesh fixators comprise tack and glue applicators. The key factors encouraging the growth of mesh segment during the forecast period are the nonpermanent mesh, availability of wide range of existing mesh types and high prices as compared others.

The open surgery segment accounted for the largest share of hernia repair in 2024-2029.

Based on surgery type, the open surgery segment is estimated to hold the largest market share of the Hernia repair market during the forecast period. While in 2024, laparoscopic surgery is expected to register the highest CAGR in the market for hernia repair during the forecast period. Time efficiency, low recurrence rate and economical approach of the technique lead to a large share of the open surgery segment.

Asia Pacific registered the highest CAGR in the market during the forecast period.

In 2024, Asia Pacific is expected to register the highest CAGR in the market for hernia repair during the forecast period. Asia Pacific comprises China, India, South Korea, Taiwan, and Singapore, and the rest of Asia Pacific. Factors such as the growing adoption of advanced treatment options, presence of a large target patient population and improving diagnosis and treatment rates are driving the growth of the APAC hernia repair market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203245450

Hernia Repair Market Dynamics:

Drivers:

1. Increasing hernia prevalence

Restraint:

1. High costs of mesh repair and availability of less-expensive approaches

Opportunities:

1. Growth potential offered by emerging markets

Challenge:

1. Dearth of expertise in laparoscopic surgery

Key Market Players of Hernia Repair Industry:

As of 2023, prominent players in hernia repair are Ethicon Inc. (US), AbbVie Inc. (US), Medtronic plc (Ireland), Becton Dickinson and Company (US), Baxter International Inc. (US), B. Braun SE (Germany), W. L. Gore & Associates (US), Cook Group Inc (US), Integra Lifesciences Holdings Corporation (US), among others.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1– 31%, Tier 2– 49%, and Tier 3– 28%
By Designation: C-level– 28%, Directors– 19%, and Others– 53%
By Region: North America– 34%, Europe– 36%, Asia Pacific– 22%, Latin America- 6%, MEA- 2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=203245450

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hernia-mesh-devices-market-203245450.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hernia Repair Market worth $5.1 billion by 2029 | MarketsandMarkets™

Wearable Healthcare Devices Market Worth $69.2 Billion | MarketsandMarkets™

“North America held the predominant portion of the wearable healthcare devices market. The wearable healthcare devices market in North America is well-established. The wearable healthcare devices market’s preeminence in North America is also influenced by a range of other factors.”

Wearable Healthcare Devices Market in terms of revenue was estimated to be worth $40.7 billion in 2023 and is poised to reach $69.2 billion by 2028, growing at a CAGR of 11.2% from 2023 to 2028 according to a new report by MarketsandMarkets™

Wearable Healthcare Devices Market in terms of revenue was estimated to be worth $40.7 billion in 2023 and is poised to reach $69.2 billion by 2028, growing at a CAGR of 11.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. In recent years, there has been substantial growth in the home healthcare market, driven primarily by the expanding geriatric population, a growing incidence of chronic diseases, and the accessibility of advanced medical devices, including wearable medical devices. These technologies facilitate the provision of high-quality care outside traditional hospital settings. As a consequence, there has been an improvement in patient compliance, the implementation of proactive treatments, enhanced patient satisfaction, and an overall elevation in the quality of care. Additionally, this approach contributes to cost reduction associated with hospital stays, as monitoring and diagnosis can now be effectively conducted in the comfort of patients’ homes. Browse through 350 market data tables and 48 figures spread across 400 pages and the in-depth TOC of the wearable healthcare devices market. Early buyers will receive a 10% customization on reports.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973

In 2022, the smartwatches segment held the largest share of the wearable healthcare devices market by product segment.

Based on product, the wearable healthcare devices market has been segmented into trackers, smartwatches, patches, and smart clothing. The smartwatches segment dominated the wearable healthcare devices market in 2022. The smartwatch market is characterized by continuous innovation. Manufacturers regularly introduce new features, sensor improvements, and software updates, ensuring that smartwatches remain at the forefront of technology and meet users’ evolving expectations. Several companies are increasingly focusing on introducing products in the market with advanced features and functionalities.

The online channels segment held the largest share of the wearable healthcare devices market by distribution channel segment in 2022.

Based on distribution channel, the wearable healthcare devices market is segmented into pharmacies, online channels, and hypermarkets. The online channels segment accounted for the largest share of the global wearable healthcare devices market in 2022. The exponential growth of e-commerce is a primary catalyst, providing consumers with a convenient and accessible platform to explore, compare, and purchase an extensive array of health-centric wearables. The wide reach facilitated by online channels ensures a global audience, enhancing market penetration and fostering increased consumer engagement. Furthermore, the convenience of 24/7 availability aligns seamlessly with the fast-paced lifestyles of modern consumers, allowing them to make informed choices at their convenience.

North America is the largest regional market for wearable healthcare devices market.

The market for wearable healthcare devices has been divided into four key geographical regions: North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America held the predominant portion of the wearable healthcare devices market. The wearable healthcare devices market in North America is well-established. The wearable healthcare devices market’s preeminence in North America is also influenced by a range of other factors. These encompass the burgeoning elderly population, resulting in an uptick in chronic ailments, the upward trajectory of healthcare expenditures, a heightened demand for improved healthcare services, government initiatives promoting digital health, the pervasive reach of 3G and 4G networks, and an increasing awareness of self-health management.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=81753973

Wearable Healthcare Devices Market Dynamics:

Drivers:

Growing awareness about lifestyle management and home healthcare
Development of technologically advanced products
Growth in geriatric population and subsequent rise in chronic diseases
Rising public-private investments for wearable devices
Increasing availability of smartphone-based applications and rising adoption of 3G/4G networks
Growing preference for wireless connectivity among healthcare providers

Restraints:

Inadequate regulatory standardization
Issues related to accuracy & analysis of wearable-generated data
Data security concerns

Opportunities:

Increasing adoption of AI and 5G

Challenge:

Patent protection of wearable healthcare devices
Limited battery life
Device design complexity

Key Market Players of Wearable Healthcare Devices Industry:

The major players operating in wearable healthcare devices market are Apple Inc. (US), Fitbit (US), OMRON Corporation (Japan), Medtronic (Ireland), Garmin Ltd. (US), GE HealthCare (US), Dexcom, Inc. (US), Abbott (US), Masimo (US), Koninklijke Philips N.V. (Netherlands), Boston Scientific Corporation (US), iRhythm Technologies, Inc. (US), CONTEC MEDICAL SYSTEMS CO. LTD. (China), Biotricity (US), MediBioSense (UK), VitalConnect (US), Cyrcadia Health (US), ten3T Healthcare (India), Minttihealth (China), Biobeat (Israel), iHealth Labs Inc. (US), VivaLNK, Inc. (US), GENTAG, Inc. (US), AiQ Smart Clothing (Taiwan), Nonin Medical (US), and Oxitone Medical (Israel).

The break-up of the profile of primary participants in the wearable healthcare devices market:

By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
By Designation: C-level – 27%, D-level – 18%, and Others – 55%
By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=81753973

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wearable Healthcare Devices Market Worth $69.2 Billion | MarketsandMarkets™

Contrast Media Market worth $9.7 billion by 2029 | MarketsandMarkets™

“The major players operating in this market are GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US), Unijules Life Sciences Ltd. (India)”

Browse 253 market data Tables and 41 Figures spread through 278 Pages and in-depth TOC on “Contrast Media Market by Type (Iodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, CT, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) – Global Forecast to 2029

Contrast Media Market in terms of revenue was estimated to be worth $6.3 billion in 2023 and is poised to reach $9.7 billion by 2029, growing at a CAGR of 7.5% from 2023 to 2029 according to a new report by MarketsandMarkets™. Growth in the contrast media market is mainly driven by the rising number of diagnostic centers and hospitals, growing approvals of contrast media, and availability of reimbursement. Increasing research on contrast media and growth opportunities in emerging economies also contribute to the growth of the market. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the contrast media market during the forecast period. However, side effects associated with the use of contrast media are restricting the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

In 2022, the iodinated contrast media segment held the largest share of the contrast media market, by type segment.

Based on type, the global contrast media market is categorized into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media. Iodinated contrast media account for the largest share of the contrast media market. The large share of this segment can be attributed to the growing number of procedures that require the use of iodinated contrast media, owing to benefits such as their versatility and their capacity to be used across multiple modalities such as X-ray and CT.

In 2022, the cardiovascular diseases segment held the largest share of the contrast media market, by indication segment.

By indication, the contrast media market has been segmented into cardiovascular diseases, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. The large share of cardiovascular diseases indication is attributed to factors rising prevalence of CVD diseases across the globe, coupled with the rise in awareness regarding early diagnosis of diseases.

North America dominates the global contrast media market.

Based on the region, the contrast media market is segmented into North America, Europe, Asia Pacific, and Rest of the world. In 2022, North America accounted for the largest contrast media market share. The large share of the region in the global market can be attributed to the increasing prevalence of chronic conditions and rising healthcare spending. Moreover, presence of key players and number of developments undertaken are helping the region gain a reasonable share in the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

Contrast Media Market Dynamics:

Drivers:

1. Increasing prevalence of chronic medical conditions

Restraints:

1. Side effects associated with the use of contrast media

Opportunities:

1. Increasing research on contrast media

Challenge:

1. Dearth of trained professionals

Key Market Players of Contrast Media Industry:

The major players operating in this market are GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US), Unijules Life Sciences Ltd. (India), JB Pharma (India), Sanochemia Pharmazeutika (Germany), TAEJOON PHARM Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ýlaç San. ve Tic. A.Þ. (Turkey), Fresenius Kabi (Germany), Biem Ilaç San. ve Tic. A.S. (Turkey), and AdvaCare (US).

The break-up of the profile of primary participants in the contrast media market:

By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25%
By Designation: C-level – 45%, D-level – 29%, and Others – 26%
By Region: North America – 35%, Europe – 27%, Asia Pacific – 32%, Rest of the World- 6%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=911

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Contrast Media Market worth $9.7 billion by 2029 | MarketsandMarkets™

Electronic Clinical Outcome Assessment (eCOA) Solution Market Worth $3.9 Billion | MarketsandMarkets™

“Prominent players in the Electronic Clinical Outcome Assessment (eCOA) Solutions market include include IQVIA (US), Medidata (US), ICON Plc (Ireland), Signant Health (US), Clario (US), Oracle Corporation (US), Medable Inc. (US)”

Electronic Clinical Outcome Assessment (eCOA) Solution Market in terms of revenue was estimated to be worth $1.8 billion in 2024 and is poised to reach $3.9 billion by 2029, growing at a CAGR of 16.6% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Electronic Clinical Outcome Assessment (eCOA) Solution Market in terms of revenue was estimated to be worth $1.8 billion in 2024 and is poised to reach $3.9 billion by 2029, growing at a CAGR of 16.6% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the Electronic Clinical Outcome Assessment (eCOA) Solutions market is driven by rise in patient centricity, increase in incidences of chronic disorders, and growing acceptance of eCOA solutions by several pharmaceutical and biotechnology companies for data collection and its analysis. As eCOA helps enhance patient engagement by facilitating patient-reported outcomes. Moreover, the increase in demand for real-world evidence across may boost the market during the forecast period. But the increase in concerns about data breaches and privacy may pose a challenge to the Electronic Clinical Outcome Assessment (eCOA) Solutions market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87857774

Hybrid model is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023.

Based on component, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into software, services, and wearable, mobile & other devices. The wearable, mobile & other devices segment is further categorized into bring your own device model (BYOD), Provisioned device model, and hybrid model. The hybrid model is the fastest growing in Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to its ability to offer a balanced and flexible approach to data collection in clinical trials. The hybrid model combines elements of both Bring Your Own Device (BYOD) and Provisioned Device models, providing a versatile solution that accommodates varying preferences and trial requirements. Hybrid model gives flexibility to the participants by offering option to use their own devices or devices provided by the study, depending on their comfort and accessibility. This flexibility reduces barriers to participation, as participants can choose the mode that aligns with their technological preferences.

By application, observational studies and real-world evidence generation is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023.

Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. Among these the observational studies and real-world evidence generation is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to an increasing emphasis on real-world data’s significance in healthcare decision-making. Moreover, the segment’s growth is due to the growing acceptance of real-world evidence (RWE) by regulatory bodies, healthcare providers, and pharmaceutical companies drives. RWE is crucial for understanding a treatment’s effectiveness, safety, and overall impact on patients in everyday clinical practice.

Pharmaceuticals and biotechnology companies are the largest end users of the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023.

Based on end users, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), medtech companies, government organizations, research centers & academic institutes, hospitals & healthcare providers, and consulting service companies. The pharmaceutical and biotechnology companies dominated the eCOA solutions market in 2023 attributing to growth in adoption of eCOA solution across by companies. As the Electronic Clinical Outcome Assessment (eCOA) slutions helps in advancing clinical trials by streamlining and enhancing the accuracy of data collection. Moreover, eCOA also helps to ensure the integrity of clinical data, facilitating regulatory compliance and improving overall study quality. For pharmaceutical and biotechnology firms, the adoption of eCOA translates into accelerated decision-making, reduced trial timelines, and enhanced patient engagement, thus these end users are dominating the market.

North America dominates the global Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023.

The Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America accounted for the largest share of the Electronic Clinical Outcome Assessment (eCOA) Solutions market. As this region is home to a significant number of pharmaceutical and biotechnology companies which are using eCOA solutions. These companies conduct extensive clinical trials, seeking efficient and accurate methods of data collection to meet rigorous regulatory standards. Moreover, the well-established healthcare infrastructure in North America, coupled with a high level of digital literacy among healthcare professionals, facilitates the seamless integration of eCOA technologies. Furthermore, the region’s leadership in research and development, coupled with substantial investments in healthcare technology, reinforces its position at the forefront of the eCOA market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=87857774

Electronic Clinical Outcome Assessment (eCOA) Solution Market Dynamics:

Drivers:

Growing preference of digital data collection and analysis

Restraints:

Lack of skilled professionals to develop & operate eCOA solutions

Opportunities:

Increase in number of clinical trials

Challenge:

Evolving Regulatory landscape and compliance requirements

Key Market Players of Electronic Clinical Outcome Assessment (eCOA) Solution Industry:

Prominent players in the Electronic Clinical Outcome Assessment (eCOA) Solutions market include include Signant Health (US), IQVIA HOLDINGS INC, (US), Oracle Corporation (US), Kayentis (France), TransPerfect (US), Obvio Health USA, Inc. (US), WCG Clinical (US), clincapture (US), Merative (US), Clario (US), Medable Inc. (US), Medidata (US), healthentia (Belgium), Veeva Systems Inc. (US), assiTek (US), Curebase Inc (US), Castor (US), EvidentIQ (Germany), Y-Prime, LLC. (US), Clinical ink (US), and ICON PUBLIC LIMITED COMPANY(Ireland).

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:

By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company’s Product managers, Purchase Heads, etc. (35%), and Others (25%).
By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)
By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=87857774

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electronic Clinical Outcome Assessment (eCOA) Solution Market Worth $3.9 Billion | MarketsandMarkets™

Ministry of Commerce of Thailand Shows Achievements of “THAIFEX – ANUGA ASIA 2024” Driving Food Industry to the Global Market, Boosting National GDP, and Generating Trade Value Over 96 Billion Baht

BANGKOK, THAILAND – June 24th, 2024 – The Ministry of Commerce of Thailand proudly announces the resounding success of the “THAIFEX – ANUGA ASIA 2024” food and beverage trade show, which was grandly held from May 28 to June 1, 2024, at IMPACT Muang Thong Thani. The event attracted more than 138,000 visitors from all over the world, driving Thai economy through trade value exceeding 96 billion baht.

Mr. Phumtham Wechayachai, Deputy Prime Minister and Minister of Commerce of Thailand, stated that the success of the THAIFEX – ANUGA ASIA 2024, organized by the Department of International Trade Promotion, Ministry of Commerce, the Thai Chamber of Commerce and Koelnmesse Germany, elevated Thailand’s food and beverage industry, significantly contributed to the national GDP, and reinforced Thailand’s vision as a global food hub aligning with the government’s ‘Thailand Vision’.

The THAIFEX – ANUGA ASIA 2024 boasted an impressive presence, featuring 3,133 food and beverage exhibitors (1,109 Thai companies and 2,024 international companies) showcasing their products across 6,238 booths from 52 countries in several regions around the world, including East Asia, ASEAN, Europe, North America, Latin America, Australia and Middle East.

The trade show attracted 138,508 visitors, including 85,850 trade visitors (19,984 international trade visitors and 65,866 Thai trade visitors) and 52,658 public visitors. The total trade value amounted to 96,265.80 million baht, with 96,041.41 million baht from trade days (651.67 million baht of immediate purchases and 95,389.74 million baht of estimated trade value within a year). Countries with the highest total purchase were Thailand, China, India, South Korea, and Malaysia, respectively. The top five product categories by sales were fine food, sweets and confectionery, drinks, frozen food, and seafood, respectively. Retail sales during the event valued 224.39 million baht. Thai businesses accounted for a significant portion of the total trade value, contributing 71,359.86 million baht.

“We aim for Thai food exports to reach over 1.4 trillion baht this year, surpassing the previous year’s figure of 1.37 trillion baht. The remarkable achievement of the THAIFEX – ANUGA ASIA 2024 undoubtedly plays a crucial role in achieving this export target,” said Mr. Phumtham.

The next THAIFEX – ANUGA ASIA is scheduled for 27-31 May 2025. Interested exhibitors can register from 1 July 2024, at 9:00 AM via the THAIFEX Online system at https://thaifex.thaichamber.org

For more information, visit www.thaifex-anuga.com

Media Contact
Company Name: Integrated Communication Co., Ltd.
Contact Person: Usanee Thavornkarn
Email: Send Email
Phone: 081 984 5500
City: Bangkok
Country: Thailand
Website: www.incom.co.th

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ministry of Commerce of Thailand Shows Achievements of \”THAIFEX – ANUGA ASIA 2024\” Driving Food Industry to the Global Market, Boosting National GDP, and Generating Trade Value Over 96 Billion Baht

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™

“Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc. (Ireland), Syneos Health (US), Parexel International Corporation (US), Thermo Fisher Scientific Inc. (US)”

Browse 506 market data Tables and 59 Figures spread through 432 Pages and in-depth TOC on “Real World Evidence Solutions Market by by Component (Data Sets: Clinical, Claims, Pharmacy, Patients, Registry, Integrated), Application (Drug & Device Development), Revenue Model (Value-based, Subscription), End User – Global Forecast to 2029

Real World Evidence Solutions Market in terms of revenue was estimated to be worth $2.0 billion in 2024 and is poised to reach $4.5 billion by 2029, growing at a CAGR of 16.5% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the Real-World Evidence Solution market is driven by the increased shift towards a value-based and upsurging aging population. Additionally, the increase in the prevalence of chronic diseases, and rising innovation in pharmaceutical and medical devices are propelling the adoption of RWE solutions and driving the market growth. Moreover, several companies are prioritizing the use of RWE solutions to help them to reduce their drug development delays. Thus, the increase in availability of healthcare data, coupled with growing need to provide high-quality care to patients, will progressively compel healthcare organizations to depend on these innovative methodologies and technologies leading to boost the market growth for the real-world evidence-based solution market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

Services accounted for the larger share of the Real-World Evidence Solution market in 2023.

On the basis component, the Real-World Evidence Solution market is segmented into services and data sets. The services accounted for the larger share of this segment in 2023. The service segment comprises of advanced analytics services and consulting services. Advanced analytical services play a crucial role in swiftly accessing, examining, and providing essential insights required by various stakeholders. The provision of cutting-edge analytical tools and technologies has allowed these services to harness the power of big data, enabling more accurate and insightful analysis of real-world patient data. This advanced analytics capability is crucial in extracting meaningful patterns and insights from diverse and vast datasets, providing a competitive edge in understanding real-world patient outcomes, treatment effectiveness, and safety profiles. Moreover, the inclusion of consulting services has allowed services segment to offer comprehensive solutions to its clients by providing expert guidance and strategic insights, the company can assist healthcare organizations in navigating the complex landscape of real-world evidence. Additionally, the growing need to transform healthcare data into actionable evidence, coupled with the aim to minimize delays in drug development and the abundance of extensive healthcare data, stands out as significant drivers propelling the expansion of this market segment.

By application, the drug development and approvals segment accounted for the largest market share in 2023.

Based on application, the Real-World Evidence Solution market is segmented into drug development and approvals, medical device development and approvals, post market surveillance, market access and reimbursement/coverage decision making, and Clinical & regulatory decision making. The drug development and approvals is bifurcated into oncology, cardiovascular disorders, neurology, immunology, and other therapeutic areas. The oncology subsegment holds the largest share of this segment in 2023. This is attributed to the increasing number of cancer cases worldwide. Due to increasing number of cancer cases several pharmaceutical companies are investing in innovative medicines for treatment of cancer. Fr instance, according to IQVIA Holdings Inc., global oncology trends article 2022, over the past decade, there has been a substantial increase in the development of products in the field of oncology, and currently, there are over 2,000 products in the pipeline.

Pharmaceutical and medical device companies are the largest end users of the Real-World Evidence Solution market

Based on end users, the Real-World Evidence Solution market is segmented into pharmaceutical and medical devices companies, healthcare payers, healthcare providers, and other end-users which includes CROs, academic institutions, patient advocacy groups, and HTA agencies. The pharmaceutical and medical device companies hold the largest share among the end-users in 2023 as these companies need data that is medically approved. As the utilization of Real-World Evidence (RWE) data plays a crucial role in facilitating the successful progression of innovative medicines through the various phases of clinical trials. Furthermore, the increasing prevalence of RWE studies employed in the drug approval process serves as a preventive measure against expensive drug recalls. These studies offer valuable analyses of how drugs perform in real-world settings, enhancing the understanding of the effectiveness and safety beyond the controlled environments of clinical trials.

North America dominates the global Real-World Evidence Solution market.

The Real-World Evidence Solution market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Real-World Evidence Solution market. This region’s dominance is due to the favorable regulatory environment and increasing adoption of EHR. Additionally, the increase in number of payers using RWE solution services is driving regional growth of the RWE evidence solution market. Moreover, the presence of key market players such as IQVIA Holdings Inc., (US), Optum (US), Oracle (US), and among others are a key factor contributing to the growth of the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991

Real World Evidence Solutions Market Dynamics:

Drivers:

Shift from volume to value-based care

Opportunities:

Growing Opportunities in emerging markets

Challenge:

Shortage of skilled professionals

Key Market Players of Real World Evidence Solutions Industry:

Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc. (Ireland), Syneos Health (US), Parexel International Corporation (US), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (US), Oracle (US), Medspace Holdings Inc. (US), Elevance Health, INC. (US), SAS Institute Inc. (US), Aetion Inc. (US), Trinetx Llc. (US), Trinity (US), PerkinElmer, Inc. (US), Cognizant Technology Solutions Corporation (US), Clinigen Group plc (UK), Cegedim Health Data (France), Verantos (US), HealthVerity, Inc. (US), Datavant (US), Syapse, Inc. (US), Tempus (US), and Flatiron Health (US).

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
By Designation: C-level (35%), Director-level (45%), and Others (20%)
By Region: North America (55%), Europe (20%), Asia Pacific (15%), Latin America (5%) and Middle East Africa (5%)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=76173991

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™

Pulmonary Arterial Hypertension Market Forecast 2034: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight

“Pulmonary Arterial Hypertension Market”

Pulmonary Arterial Hypertension companies are Merck, United Therapeutics, Respira Therapeutics, Gossamer Bio, Ferrer, Liquidia Technologies, Tenax Therapeutics, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Enzyvant Therapeutics, Cereno Scientific, AstraZeneca, PhaseBio Pharmaceutical, and more.

(Albany, USA) DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Pulmonary Arterial Hypertension market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Pulmonary Arterial Hypertension treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Pulmonary Arterial Hypertension market.

Request for a Free Sample Report @ Pulmonary Arterial Hypertension Market Forecast

Some facts of the Pulmonary Arterial Hypertension Market Report are:

The Pulmonary Arterial Hypertension market size in the seven major markets was approximately USD 4,838.8 million in 2022, which is further expected to increase by 2034.
The United States accounts for the largest Pulmonary Arterial Hypertension market size compared to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
Leading Pulmonary Arterial Hypertension companies working in the market are Merck, United Therapeutics, Respira Therapeutics, Gossamer Bio, Ferrer, Liquidia Technologies, Tenax Therapeutics, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Enzyvant Therapeutics, Cereno Scientific, AstraZeneca, PhaseBio Pharmaceutical, and others.
Various therapies that are expected to enter the Pulmonary Arterial Hypertension market during the forecast period include Sotatercept (MK-7962)(Merck), ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), seralutinib(GB002) (Gossamer Bio), YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies), and TNX201 (Tenax Therapeutics).
A multicenter, double-blind, phase 3 trial evaluated sotatercept in adults with PAH (World Health Organization functional class II or III). Participants received subcutaneous sotatercept or placebo every 3 weeks. The study aimed to assess the efficacy and safety of this novel therapeutic option3.
On March 2024, Aerovate Therapeutics announced results of IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
On April 2023, Acceleron Pharma announced results of a Phase 2, double-blind, randomized, placebo-controlled, parallel-group study of sotatercept plus standard of care (SOC) versus placebo plus SOC in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg by subcutaneous (SC) injection every 21 days for a period of 24 weeks in the placebo-controlled treatment period of the study while on SOC therapy. Evaluations will include changes in pulmonary vascular resistance (PVR), 6-minute walk distance (6MWD), quality of life questionnaires, echocardiographic parameters, and safety. Participants who have not discontinued early from the placebo-controlled treatment period and have had their post-treatment period PVR assessment will be able to continue into the 30-month extension period in which sotatercept-treated participants will receive their latest dose level of sotatercept SC every 21 days and placebo-treated participants will be re-randomized 1:1 to receive sotatercept 0.3 mg/kg SC or sotatercept 0.7 mg/kg SC every 21 days while on SOC therapy.
On April 2023, Gossamer Bio Inc. announced results of An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH).

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a progressive disorder characterized by high blood pressure in the arteries of the lungs, leading to increased workload on the heart and potential heart failure. It results from the narrowing and tightening of the small arteries in the lungs, causing resistance to blood flow. Common symptoms include shortness of breath, fatigue, chest pain, dizziness, and fainting. PAH can occur idiopathically or secondary to other conditions such as connective tissue diseases, congenital heart defects, or chronic liver disease.

Diagnosis typically involves echocardiography, right heart catheterization, and other imaging tests to assess pulmonary artery pressure and evaluate the severity of the condition. Treatment aims to improve symptoms, slow disease progression, and enhance quality of life. Therapeutic approaches may include medications to dilate blood vessels, reduce blood clotting, and manage fluid retention, as well as lifestyle modifications and, in severe cases, lung transplantation. Early detection and comprehensive management are crucial for optimizing outcomes in PAH patients.

Learn more about Pulmonary Arterial Hypertension treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Pulmonary Arterial Hypertension Treatment Market

Pulmonary Arterial Hypertension Market

The Pulmonary Arterial Hypertension market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Pulmonary Arterial Hypertension market trends by analyzing the impact of current Pulmonary Arterial Hypertension therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Pulmonary Arterial Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pulmonary Arterial Hypertension market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pulmonary Arterial Hypertension market in 7MM is expected to witness a major change in the study period 2020-2034.

Pulmonary Arterial Hypertension Market Drivers:

Government Support for Drug Development: Governments and healthcare authorities play a crucial role in advancing research and ensuring effective treatments for PAH. Financial support, regulatory guidance, and incentives facilitate drug discovery and development.
Rising Prevalence of PAH: The growing occurrence of PAH encourages governments and pharmaceutical companies to invest in drug research. In the U.S. and Europe, PAH affects approximately 32.5 individuals per million population1.
Favorable Reimbursement Policies: Accessible reimbursement policies enhance patient affordability and encourage treatment adoption.
Research and Development Activities: Substantial R&D efforts in the field of PAH contribute to positive market growth. For instance, a unique cell-based approach is being explored in clinical trials1.
Collaboration with Regulatory Agencies: Regulatory bodies like the U.S. FDA and the European Medicines Agency streamline approval processes for PAH drugs through mechanisms such as fast-track designations and priority review pathways.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension epidemiology section provides insights into the historical and current Pulmonary Arterial Hypertension patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pulmonary Arterial Hypertension market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Pulmonary Arterial Hypertension Epidemiology @ Pulmonary Arterial Hypertension Prevalence

Pulmonary Arterial Hypertension Drugs Uptake

This section focuses on the uptake rate of the potential Pulmonary Arterial Hypertension drugs recently launched in the Pulmonary Arterial Hypertension market or expected to be launched in 2020-2034. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Pulmonary Arterial Hypertension Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Pulmonary Arterial Hypertension market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Pipeline Development Activities

The Pulmonary Arterial Hypertension report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Pulmonary Arterial Hypertension key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Pulmonary Arterial Hypertension pipeline development activities @ Pulmonary Arterial Hypertension Therapies and Drugs

Pulmonary Arterial Hypertension Therapeutics Assessment

Major key companies are working proactively in the Pulmonary Arterial Hypertension Therapeutics market to develop novel therapies which will drive the Pulmonary Arterial Hypertension treatment markets in the upcoming years are Merck, United Therapeutics, Respira Therapeutics, Gossamer Bio, Ferrer, Liquidia Technologies, Tenax Therapeutics, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Enzyvant Therapeutics, Cereno Scientific, AstraZeneca, PhaseBio Pharmaceutical, and others.

Learn more about the emerging Pulmonary Arterial Hypertension therapies & key companies @ Pulmonary Arterial Hypertension Clinical Trials and FDA Approvals

Pulmonary Arterial Hypertension Report Key Insights

1. Pulmonary Arterial Hypertension Patient Population

2. Pulmonary Arterial Hypertension Market Size and Trends

3. Key Cross Competition in the Pulmonary Arterial Hypertension Market

4. Pulmonary Arterial Hypertension Market Dynamics (Key Drivers and Barriers)

5. Pulmonary Arterial Hypertension Market Opportunities

6. Pulmonary Arterial Hypertension Therapeutic Approaches

7. Pulmonary Arterial Hypertension Pipeline Analysis

8. Pulmonary Arterial Hypertension Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Pulmonary Arterial Hypertension Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis

4. Pulmonary Arterial Hypertension Market Overview at a Glance

5. Pulmonary Arterial Hypertension Disease Background and Overview

6. Pulmonary Arterial Hypertension Patient Journey

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Arterial Hypertension Unmet Needs

10. Key Endpoints of Pulmonary Arterial Hypertension Treatment

11. Pulmonary Arterial Hypertension Marketed Products

12. Pulmonary Arterial Hypertension Emerging Therapies

13. Pulmonary Arterial Hypertension Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Arterial Hypertension Market Outlook (7 major markets)

16. Pulmonary Arterial Hypertension Access and Reimbursement Overview

17. KOL Views on the Pulmonary Arterial Hypertension Market

18. Pulmonary Arterial Hypertension Market Drivers

19. Pulmonary Arterial Hypertension Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Market Forecast 2034: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight

Multiple Sclerosis Market Analysis 2034: FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

“Multiple Sclerosis Market”

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Bristol-Myers Squibb, TG Therapeutics, Roche, Atara Biotherapeutics, Immunic, Celgene, Anokion, Sanofi, Actelion, Biogen, RemeGen, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, GlaxoSmithKline, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, and others.

(Albany, USA) DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Multiple Sclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Multiple Sclerosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Multiple Sclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Multiple Sclerosis market.

Request for a Free Sample Report @ Multiple Sclerosis Market Forecast

Some facts of the Multiple Sclerosis Market Report are:

According to DelveInsight, Multiple Sclerosis market size is expected to grow at a decent CAGR by 2034.
Leading Multiple Sclerosis companies working in the market are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, and others.
Key Multiple Sclerosis Therapies expected to launch in the market are NeuroVax, CNM-Au8, [F-18]PBR06, IMS001, Tolebrutinib (SAR442168), 11C-BMS-986196, Ublituximab, Ocrelizumab, ATA188, IMU-838, RPC-1063, ANK-700, SAR441344 IV, Ponesimod, BIIB017, MYOBLOC, Prosetin, and others.
On March 2024, Novartis announced results of a non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to describe the Quality of Life of Multiple Sclerosis Patients after Initiation of Treatment with Ofatumumab.
On March 2024, Bayer announced results on INFORM – Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy – a Register-Based Drug Utilisation Study in Finland and Sweden.
On February 2024, Novartis announced results of a 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension.
On January 2024, Hoffmann-La Roche announced a Phase Ib, Open-Label, Multicentre Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis.
On September 2023, Biogen announced results on a Multicenter, Prospective Cohort Study to Document the Immunization Status of Multiple Sclerosis Patients in Germany With Focus on Anti-SARS-CoV-2 Vaccination Response

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), including the brain and spinal cord. In Multiple sclerosis, the immune system mistakenly attacks the protective covering of nerve fibers, called myelin, leading to inflammation, scarring (sclerosis), and disruptions in nerve signalling.

Multiple sclerosis symptoms vary widely depending on the location and extent of nerve damage but often include fatigue, weakness, numbness or tingling, muscle spasms, coordination problems, and difficulties with vision, cognition, and mood. These symptoms may come and go or worsen over time, leading to periods of relapse (exacerbations) followed by partial or complete recovery, and eventual progression of disability.

The exact cause of Multiple sclerosis is unknown, but a combination of genetic predisposition, environmental factors, and immune system dysfunction likely contribute to its development. Factors such as vitamin D deficiency, smoking, and certain viral infections have been implicated in increasing the risk of Multiple sclerosis.

Diagnosis of Multiple sclerosis typically involves clinical evaluation, neurological exams, imaging studies (such as MRI), and analysis of cerebrospinal fluid. Although there is no cure for Multiple sclerosis, various treatments aim to manage symptoms, slow disease progression, and modify the immune response. These treatments may include disease-modifying therapies, corticosteroids for acute relapses, symptomatic management, and rehabilitation strategies to improve quality of life and function for individuals living with Multiple sclerosis.

Learn more about Multiple Sclerosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Multiple Sclerosis Treatment Market

Multiple Sclerosis Market

The Multiple Sclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Multiple Sclerosis market trends by analyzing the impact of current Multiple Sclerosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Multiple Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Multiple Sclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Multiple Sclerosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Multiple Sclerosis Epidemiology

The Multiple Sclerosis epidemiology section provides insights into the historical and current Multiple Sclerosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Multiple Sclerosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Multiple Sclerosis Epidemiology @ Multiple Sclerosis Prevalence

Multiple Sclerosis Drugs Uptake

This section focuses on the uptake rate of the potential Multiple Sclerosis drugs recently launched in the Multiple Sclerosis market or expected to be launched in 2020-2034. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Multiple Sclerosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Multiple Sclerosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Sclerosis Pipeline Development Activities

The Multiple Sclerosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Multiple Sclerosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Multiple Sclerosis pipeline development activities @ Multiple Sclerosis Therapies and Drugs

Multiple Sclerosis Therapeutics Assessment

Major key companies are working proactively in the Multiple Sclerosis Therapeutics market to develop novel therapies which will drive the Multiple Sclerosis treatment markets in the upcoming years are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, and others.

Learn more about the emerging Multiple Sclerosis therapies & key companies @ Multiple Sclerosis Clinical Trials and FDA Approvals

Multiple Sclerosis Report Key Insights

1. Multiple Sclerosis Patient Population

2. Multiple Sclerosis Market Size and Trends

3. Key Cross Competition in the Multiple Sclerosis Market

4. Multiple Sclerosis Market Dynamics (Key Drivers and Barriers)

5. Multiple Sclerosis Market Opportunities

6. Multiple Sclerosis Therapeutic Approaches

7. Multiple Sclerosis Pipeline Analysis

8. Multiple Sclerosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Multiple Sclerosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Therapies

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (7 major markets)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Market Analysis 2034: FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

Limb Girdle Muscular Dystrophy (LGMD) Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

“Limb Girdle Muscular Dystrophy (LGMD) Market”

Limb Girdle Muscular Dystrophy companies are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.

(Albany, USA) DelveInsight’s “Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Limb Girdle Muscular Dystrophy, historical and forecasted epidemiology as well as the Limb Girdle Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Limb Girdle Muscular Dystrophy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Limb Girdle Muscular Dystrophy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Limb Girdle Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Limb Girdle Muscular Dystrophy market.

Request for a Free Sample Report @ Limb Girdle Muscular Dystrophy Market Forecast

Some facts of the Limb Girdle Muscular Dystrophy Market Report are:

According to DelveInsight, Limb Girdle Muscular Dystrophy market size is expected to grow at a decent CAGR by 2032.
Leading Limb Girdle Muscular Dystrophy companies working in the market are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
Key Limb Girdle Muscular Dystrophy Therapies expected to launch in the market are SRP-6004, LION-101, BBP-418 (ribitol), and others.
On February 2024, Sarepta Therapeutics announced results of a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).
On October 2023, aTyr Pharma, Inc. announced results of an Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies.
On April 2023, ML Bio Solutions announced results of an open label study in ambulatory and non-ambulatory subjects with LGMD2I (also known as LGMD R9) previously enrolled in the natural history Study MLB-01-001. This is a study to determine the safety and tolerability of ascending dose levels of BBP-418 in those subjects.

Limb Girdle Muscular Dystrophy Overview

Limb-girdle muscular dystrophy (LGMD) encompasses a group of genetic disorders characterized by progressive weakness and wasting of the muscles, primarily affecting the muscles around the shoulders and hips. It can manifest at any age, with onset typically occurring in childhood, adolescence, or adulthood. LGMD is caused by mutations in various genes responsible for muscle function and structure.

Limb-girdle muscular dystrophy (LGMD) Symptoms vary widely among individuals but often include difficulty rising from a seated position, climbing stairs, and lifting objects. As the disease progresses, individuals may experience muscle weakness and atrophy in other areas of the body, leading to mobility limitations and potential respiratory complications in severe cases.

Limb-girdle muscular dystrophy (LGMD) Diagnosis involves a combination of clinical evaluation, genetic testing, electromyography (EMG), and muscle biopsy. While there is currently no cure for LGMD, management focuses on symptom relief, maintaining mobility, and optimizing quality of life. This may involve physical therapy, assistive devices, respiratory support, and ongoing monitoring for potential complications.

Research into potential treatments, including gene therapy and pharmacological interventions, is ongoing and offers hope for improved outcomes in the future. Additionally, supportive resources and patient advocacy organizations play a crucial role in providing information, support, and community for individuals and families affected by Limb-girdle muscular dystrophy (LGMD).

Learn more about Limb Girdle Muscular Dystrophy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Limb Girdle Muscular Dystrophy Treatment Market

Limb Girdle Muscular Dystrophy Market

The Limb Girdle Muscular Dystrophy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb Girdle Muscular Dystrophy market trends by analyzing the impact of current Limb Girdle Muscular Dystrophy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Limb Girdle Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Limb Girdle Muscular Dystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight’s’ estimates, the limb girdle muscular dystrophy market in 7MM is expected to show a positive growth, during the forecast period (2023–2032), mainly attributed to anticipated launch of emerging therapy and the increasing cases of LGMD.

Limb Girdle Muscular Dystrophy Epidemiology

The Limb Girdle Muscular Dystrophy epidemiology section provides insights into the historical and current Limb Girdle Muscular Dystrophy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Limb Girdle Muscular Dystrophy market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Limb Girdle Muscular Dystrophy Epidemiology @ Limb Girdle Muscular Dystrophy Prevalence

Limb Girdle Muscular Dystrophy Drugs Uptake

This section focuses on the uptake rate of the potential Limb Girdle Muscular Dystrophy drugs recently launched in the Limb Girdle Muscular Dystrophy market or expected to be launched in 2019-2032. The analysis covers the Limb Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Limb Girdle Muscular Dystrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Limb Girdle Muscular Dystrophy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Currently, there is no known cure for LGMD. However, there are supportive therapies designed to manage and alleviate its symptoms. The approach to LGMD management is individualized, focusing on addressing specific symptoms that each patient experiences. Treatment options may involve physical and occupational therapy to enhance muscle strength and prevent contractures, the utilization of assistive devices like canes, braces, walkers, or wheelchairs to aid mobility, corrective surgery for skeletal issues like scoliosis, and regular monitoring of cardiac and respiratory health for potential complications associated with certain LGMD subtypes.

Limb Girdle Muscular Dystrophy Pipeline Development Activities

The Limb Girdle Muscular Dystrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Limb Girdle Muscular Dystrophy key players involved in developing targeted therapeutics.

Limb-girdle Muscular Dystrophy Pipeline Therapies and Companies

SRP-6004: Sarepta Therapeutics, Inc.
LION-101: Asklepios Biopharmaceutical, Inc.
BBP-418 (ribitol): ML Bio Solutions, Inc.
And Many Others

Request for a sample report to understand more about the Limb Girdle Muscular Dystrophy pipeline development activities @ Limb Girdle Muscular Dystrophy Drugs and Therapies

Limb Girdle Muscular Dystrophy Therapeutics Assessment

Major key companies are working proactively in the Limb Girdle Muscular Dystrophy Therapeutics market to develop novel therapies which will drive the Limb Girdle Muscular Dystrophy treatment markets in the upcoming years are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.

Learn more about the emerging Limb Girdle Muscular Dystrophy therapies & key companies @ Limb Girdle Muscular Dystrophy Clinical Trials and FDA Approvals

Limb Girdle Muscular Dystrophy Report Key Insights

1. Limb Girdle Muscular Dystrophy Patient Population

2. Limb Girdle Muscular Dystrophy Market Size and Trends

3. Key Cross Competition in the Limb Girdle Muscular Dystrophy Market

4. Limb Girdle Muscular Dystrophy Market Dynamics (Key Drivers and Barriers)

5. Limb Girdle Muscular Dystrophy Market Opportunities

6. Limb Girdle Muscular Dystrophy Therapeutic Approaches

7. Limb Girdle Muscular Dystrophy Pipeline Analysis

8. Limb Girdle Muscular Dystrophy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Limb Girdle Muscular Dystrophy Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Limb Girdle Muscular Dystrophy Competitive Intelligence Analysis

4. Limb Girdle Muscular Dystrophy Market Overview at a Glance

5. Limb Girdle Muscular Dystrophy Disease Background and Overview

6. Limb Girdle Muscular Dystrophy Patient Journey

7. Limb Girdle Muscular Dystrophy Epidemiology and Patient Population

8. Limb Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Limb Girdle Muscular Dystrophy Unmet Needs

10. Key Endpoints of Limb Girdle Muscular Dystrophy Treatment

11. Limb Girdle Muscular Dystrophy Marketed Products

12. Limb Girdle Muscular Dystrophy Emerging Therapies

13. Limb Girdle Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Limb Girdle Muscular Dystrophy Market Outlook (7 major markets)

16. Limb Girdle Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Limb Girdle Muscular Dystrophy Market

18. Limb Girdle Muscular Dystrophy Market Drivers

19. Limb Girdle Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Limb Girdle Muscular Dystrophy (LGMD) Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

Pharmacogenomics Application Analysis & Current Trends by 2028 | MarketsandMarkets™

“Browse 369 market data Tables and 56 Figures spread through 396 Pages and in-depth TOC on “Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application(Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) – Global Forecast to 2028”

Pharmacogenomics Market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028 according to a new report by MarketsandMarkets™

Pharmacogenomics Market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market. However, concern regarding drug response variability, and challenges in data integration and interpretation are the major restraining factors of the pharmacogenomics market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251

The kits & reagents segment accounted for the largest share by product & service in the pharmacogenomics market in 2022.

By product & service, the pharmacogenomics market has been further categorized kits & reagents and service. Kits & reagents accounted for the largest share of the pharmacogenomics market in 2022. The pivotal role played by kits and reagents in the execution of pharmacogenomic tests, combined with the rising adoption of personalized medicine and advancements in genomic technologies, contributes significantly to the expansion of this segment within the pharmacogenomics market.

The sequencing segment is expected to grow at a higher rate during the forecast period.

Based on technology, the pharmacogenomics market has been segmented into sequencing, PCR, microarray, and other technologies. In 2022, the sequencing segment accounted for the largest share of the pharmacogenomics market is expected to grow at a higher growth rate during the forecast period of 2023-2028. Sequencing technologies play a crucial role in precisely and effectively handling genomic data, facilitating the identification of nucleotide alterations impacting drug metabolism and response. The progress in developing novel sequencing technologies and reagents further propels the evolution of pharmacogenomics research, facilitating the identification and functional understanding of genetic variants associated with drug metabolism and response.

The cancer segment accounted for the largest share of the disease area segment in the pharmacogenomics market in 2022.

Based on disease area, the pharmacogenomics market has been segmented into cancer, cardiovascular, neurological diseases, and other diseases. In 2022, the cancer segment accounted for the largest share of the pharmacogenomics market. The expansion of the pharmacogenomics market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.

The North America region accounted for the largest share of the pharmacogenomics market in 2022.

The pharmacogenomics market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.

Request Sample Pages: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251

Pharmacogenomics Market Dynamics:

Drivers:

1. Growing incidence and prevalence of chronic and genetic diseases

2. Rising investments and funding to support genomic projects

3. Rising incidence of cancer

4. Increasing collaborations and partnerships between key players and research institutes

5. Increasing focus on translational approach to optimize drug development processes

Restraint:

1. Challenges in data integration and interpretation

2. Issues related to drug response variabilities

Opportunities:

1. Use of genomics in specialized/personalized medicine

2. AI in pharmacogenomics

3. Increasing cost-effectiveness of pharmacogenomics testing

Challenge:

1. Ethical and regulatory hurdles

2. Growing concerns related to patient privacy and data access

Key Market Players of Pharmacogenomics Industry:

Key players in the pharmacogenomics market Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), BGI (China), Novogene Co., Ltd. (China), SOPHiA GENETICS (Switzerland), Fios Genomics (UK), Personalis, Inc. (US), BioAI Health Inc. (US), NeoGenomics Laboratories (US), and Macrogen, Inc. (South Korea).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
By Region: North America -30%, Europe -20%, Asia-Pacific -30%, Latin America -15% and Middle East & Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142682251

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pharmacogenomics Application Analysis & Current Trends by 2028 | MarketsandMarkets™